Peninsula biotech stock loses 80% after eye drug's late-stage study fails By: San Francisco Business Times via Business Journals February 23, 2022 at 18:00 PM EST The company still has a quartet of late-stage trials with the drug in various eye diseases and more than $700 million in cash. Read More >>
